2022
Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides
KOS, Jiří; Gilles DEGOTTE; Dominika PINDJAKOVA; Tomáš STRHÁRSKY; Timotej JANKECH et al.Basic information
Original name
Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides
Authors
KOS, Jiří; Gilles DEGOTTE; Dominika PINDJAKOVA; Tomáš STRHÁRSKY; Timotej JANKECH; Tomáš GONĚC; Pierre FRANCOTTE; Michel FREDERICH and Josef JAMPILEK
Edition
Molecules, Basel, MDPI, 2022, 1420-3049
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Switzerland
Confidentiality degree
is not subject to a state or trade secret
References:
Impact factor
Impact factor: 4.600
Marked to be transferred to RIV
Yes
RIV identification code
RIV/00216224:14110/22:00127693
Organization unit
Faculty of Medicine
UT WoS
EID Scopus
Keywords in English
cinnamanilides; antiplasmodial activity; Plasmodium; structure-activity relationships
Tags
International impact, Reviewed
Changed: 27/1/2023 10:52, Mgr. Tereza Miškechová
Abstract
In the original language
Due to the urgent need of innovation in the antimalarial therapeutic arsenal, a series of thirty-seven ring-substituted N-arylcinnamanilides prepared by microwave-assisted synthesis were subjected to primary screening against the chloroquine-sensitive strain of P. falciparum 3D7/MRA-102. The lipophilicity of all compounds was experimentally determined as the logarithm of the capacity factor k, and these data were subsequently used in the discussion of structure-activity relationships. Among the screened compounds, fourteen derivatives exhibited IC50 from 0.58 to 31 µM, whereas (2E)-N-(4-bromo-2-chlorophenyl)-3-phenylprop-2-enamide (24) was the most effective agent (IC50 = 0.58 µM). In addition, (2E)-N-[2,6-dibromo-4-(trifluoromethyl)- phenyl]-3-phenylprop-2-enamide (36), (2E)-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-phenylprop- 2-enamide (18), (2E)-N-(2-bromo-5-fluorophenyl)-3-phenylprop-2-enamide (23), and (2E)-3-phenyl-N-(3,4,5-trichlorophenyl)prop-2-enamide (33) demonstrated efficacy in the IC50 range from 2.0 to 4.3 µM, comparable to the clinically used standard chloroquine. The results of a cell viability screening performed using THP1-Blue™ NF-κB cells showed that none of these highly active compounds displayed any significant cytotoxic effect up to 20 μM, which makes them promising Plasmodium selective substances for further investigations.